Friday - December 26, 2025

Creative BioMart Expands Native Proteins Line to Support High-fidelity Biological Research

Creative BioMart, a leader in serving science with quality recombinant proteins, and custom protein manufacturing techniques, is pleased to announce the latest updates to its native protein portfolio, helping researchers achieve physiologically relevant results in assays, functional studies, and diagnostic … Continue reading

PEMAC Supports U.S. Life Sciences with Proven Maintenance and Reliability Solutions

Aligned with Elecosoft’s established U.S. operations, PEMAC continues to deliver trusted CMMS and reliability software that drives compliance, performance, and sustainability. HOUSTON – December 23, 2025 – PEMAC, a leading provider of Computerized Maintenance Management System (CMMS) and reliability software, today … Continue reading

Santa’s Rally: CMCT, SURG, SIDU, MYSE, AZI – Stocks Under $5 to Watch Now – More Inside

As year-end positioning accelerates, the traditional Santa’s Rally is shining a spotlight on small-cap and micro-cap stocks under $5 showing renewed momentum, rising volume, and investor awareness. These names are drawing attention across technology, fintech, media, space, and consumer sectors—areas … Continue reading

Allergic Rhinitis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Allergic Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Allergic Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading

Alpha Thalassemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Alpha Thalassemia pipeline constitutes 3+ key companies continuously working towards developing 3+ Alpha Thalassemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading